glp 1 agonist in ckd GLP1 Receptor Agonists vs SGLT2-I Preventing in T2DM: An Interview – AJKD Blog Kidney and Cardiovascular Outcomes Among
Description
Perreault, L., et al
Diabetes Care 48 (7), 10571082
When P.B.s A1c rose to 6.3%, (prediabetes range) in November 2022 and he weighed in at 240 lbs, his primary care provider suggested he take the medication Mounjaro at the starting 2.5 mg dose for four weeks
FIGURE 3 Taken together, these mechanistic data and large-scale epidemiological findings point to a possible protective effect of GLP-1RAs against selected OACs
